Recent Posts

Pages: [1] 2 3 ... 10
DiPIA / Thank You
« Last post by GE Adm Peter on February 23, 2017, 10:25:22 AM »
Thank you for interacting with us over the years on this forum. This community is now being archived and will only be available as a source of additional information, but no new posts can be published at this time.

This forum exists as a free resource, but it is not intended as a place to resolve product or service issues. If you have a technical support inquiry or a customer service request, we recommend that you contact us
DiPIA / Discovery and early-stage development of biotherapeutic antibodies
« Last post by GE-Robert on May 12, 2016, 05:31:12 AM »
During discovery and early development of antibodies, thousands of antibodies are screened and evaluated in several cycles, to arrive at a clinical lead candidate. The lead candidate has the desired functional properties and ideally developability aspects have been considered to facilitate manufacturing and to avoid pitfalls in clinical studies. In the recent white paper, Biacore™ systems in discovery and early-stage development of biotherapeutic antibodies, I have tried to describe how Biacore instruments, software, sensor chips and kits support the execution and evaluation of a number of different screening and characterization assays. The paper is quite short and consists of 10 pages of text and figures and includes 40 references to relevant topics. It is included as an attachment.
DiPIA / New tools for data analysis
« Last post by GE-Robert on April 11, 2016, 11:59:05 PM »
Last year Biacore T200 evaluation software was updated with a tool called "Sensorgram comparison". To learn more about how it can be used, please copy and paste this link into your browser:

It will allow you to download the article: Comparison of surface plasmon resonance binding curves for
characterization of protein interactions and analysis of screening data. Published in Analytical Biochemistry, vol 5012, 2016, p 53 to 63.

The link is valid until May 31.

DiPIA / Biacore in late stage antibody development
« Last post by GE-Robert on March 30, 2016, 01:23:32 AM »
Biacore™ systems are widely used to support and guide selection of antibody candidates and for characterization of antibodies in late stage development and manufacturing. In the enclosed white paper (WP) “Biacore™ concentration and ligand-binding analyses in late stage development and quality control of biotherapeutics” I review how Biacore supports analysis of critical quality attributes. The WP includes examples of concentration analysis, target-, FcgammaR-, FcRn– and C1q binding. It further illustrates the use of binding mode specific reagents for analysis of higher order structure and introduces sensorgram comparison and CFCA as analytical tools for antibody characterization. It is supported by 51 literature references.

DiPIA / FcRn antibody analyses using Biotin Capture Kit and Dual/Co-inject
« Last post by GE Asa on March 18, 2016, 05:29:07 AM »

Enclosed is a presentation showing how antibody interactions with biotinylated FcRn (neonatal receptor) are facilitated using the Biotin Capture Kit.

Since studies in different pHs may be relevant for these interactions Dual inject (or Co-inject for some systems) can also help getting valuable data. (In e.g. Biacore T200 Dual inject is found under the command "General" in Method Builder)

Best regards,
DiPIA / New Biacore Vaccine white paper
« Last post by GE Asa on February 25, 2016, 12:39:08 AM »

attached is a new paper showing examples on how Biacore is used for vaccine development and analysis.

Best regards,
DiPIA / Biacore S200 software demo videos
« Last post by GE Marie W on February 12, 2016, 08:34:17 AM »
These Biacore S200 software videos are really great...take a look!

You can view: Kinetics, Competition with ABA-injection, Clean screen, Binding level screen and Affinity screen.
DiPIA / New AppNote - Direct measurement of challenging target-ligand interactions
« Last post by GE Marie W on February 04, 2016, 02:20:13 AM »
Do you know that the Biacore S200 enables kinetic characterisation at sub-resonance unit response levels
and simplifies competition assays? Read the AppNote to find out more...

- Confidently analyse challenging interactions where the target may only be partially active
- Use low surface densities to obtain excellent results at milli-RU levels
- Eliminate the need to add competitor to running buffer with ABA injection
- Test different competitors in the same experiment directly from the microplate
DiPIA / A change of buffer may do the trick both for small molecules and crude samples
« Last post by GE Asa on January 29, 2016, 02:59:30 AM »

both for small molecules and e.g crude samples a change of buffer or an additive can do wonders for the data. These are two references where buffer composition was crucial:

Small molecule interactions with protein phosphatases / P. Stenlund et al. / Anal. Biochem. 353 (2006) 217–225.

Increased sensitivity of SPR assays in plasma through efficient parallel assay optimization / A. Moberg et al. / Journal of Pharmaceutical and Biomedical Analysis 78– 79 (2013) 224– 232

Please add any other paper on this subject you may have

DiPIA / Tip of the day: Surface preparation for small molecules
« Last post by GE Marie W on January 25, 2016, 07:35:46 AM »
Tipof the day: Surface preparation for small molecules (low molecular weight compounds)

  • Sensor chip CM5 is recommended. If sufficient ligand levels cannot be obtained, then use the high capacity Sensor Chip CM7. It provides a high surface binding capacity and relatively low levels of non-specific binding.
  • Generally, direct immobilization of target proteins is recommended.
  • Capture might be an alternative for small molecule screens (not recommended for fragment screening though): Capture minimizes time spent on finding suitable immobilization and regeneration conditions. Capture will require larger volumes of target molecule. Due to variations in capture levels, low responses can be difficult to compare reliably.
  • Immobilization levels should be high (typically ~10 000 RU for medium-sized protein targets).
Pages: [1] 2 3 ... 10